Robert C Axtell

US Patent:

20110243893, Oct 6, 2011

Filed:

Feb 11, 2011

Appl. No.:

13/026173

Inventors:

Robert C. Axtell - Menlo Park CA, US
Lawrence Steinman - Stanford CA, US
May H. Han - Menlo Park CA, US
Brigit A. de Jong - Nijmegen, NL
Chander Raman - Birmingham AL, US
Michael Walker - Carlsbad CA, US
Jing Shi - Carlsbad CA, US

International Classification:

A61K 38/21
A61K 38/02
A61K 31/225
A61K 39/395
A61P 29/00
A61P 25/00
G06F 19/00

US Classification:

424 856, 514 11, 514547, 4241421, 702 19

Abstract:

Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.

US Patent:

20110250206, Oct 13, 2011

Filed:

Feb 11, 2011

Appl. No.:

13/026181

Inventors:

Robert C. Axtell - Menlo Park CA, US
Lawrence Steinman - Stanford CA, US
May H. Han - Menlo Park CA, US
Brigit A. de Jong - Nijmegen, NL
Chander Raman - Birmingham AL, US
Michael Walker - Carlsbad CA, US
Jing Shi - Carlsbad CA, US
Tito A. Serafini - Belmont CA, US

International Classification:

A61K 39/395
A61P 3/10
A61P 11/06
G06F 19/00
A61P 1/16
A61P 25/16
A61P 9/10
A61P 3/04
A61P 29/00
A61P 11/00

US Classification:

4241421, 4241451, 702 19

Abstract:

Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.

US Patent:

20130046015, Feb 21, 2013

Filed:

Feb 11, 2011

Appl. No.:

13/577579

Inventors:

Robert C. Axtell - Menlo Park CA, US
Lawrence Steinman - Stanford CA, US

International Classification:

A61K 31/225
A61P 25/00
A61P 29/00

US Classification:

514548

Abstract:

Compositions and methods are provided for the treatment of IL-17-type inflammatory demyelinating diseases with inhibitors of granulocyte function, e.g. elastase inhibitors. Diseases of interest include multiple sclerosis, neuromyelitis optica, animal models of such diseases, etc. In some embodiments pharmaceutical formulations comprising an elastase inhibitor in an effective dose for treatment of IL-17-type inflammatory demyelinating disease and a pharmaceutically acceptable excipient are provided. Patients may be classified into subtypes prior to treatment, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest.

US Patent:

20200017597, Jan 16, 2020

Filed:

Sep 25, 2019

Appl. No.:

16/582034

Inventors:

- Oklahoma City OK, US
Robert C. AXTELL - Oklahoma City OK, US

Assignee:

OKLAHOMA MEDICAL RESEARCH FOUNDATION - Oklahoma City OK

International Classification:

C07K 16/28
A61K 45/06
A61K 39/395
G01N 33/68

Abstract:

The present disclosure provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject. It also provides for treatment of multiple sclerosis (MS) in a subject.

US Patent:

20170247462, Aug 31, 2017

Filed:

Jun 29, 2015

Appl. No.:

15/320397

Inventors:

- Oklahoma City OK, US
Robert C. AXTELL - Oklahoma City OK, US

Assignee:

OKLAHOMA MEDICAL RESEARCH FOUNDATION - Oklahoma City OK

International Classification:

C07K 16/28
A61K 45/06
A61K 39/395
G01N 33/68

Abstract:

The present disclosure provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject. It also provides for treatment of multiple sclerosis (MS) in a subject. Thus, in accordance with the present disclosure, there is provided a method for treating a subject having neuromyelitis optica (NMO) comprising administering to said subject an inhibitor of B-cell activating factor (BAFF) and/or an inhibitor or proliferating inducing ligand (APRIL).

US Patent:

20160054320, Feb 25, 2016

Filed:

Apr 4, 2014

Appl. No.:

14/781885

Inventors:

- Palo Alto CA, US
Robert C. Axtell - Oklahoma City OK, US
Jeffrey Edward Dunn - San Jose CA, US

International Classification:

G01N 33/569
A61K 31/785
A61K 38/21
G01N 15/14

Abstract:

Compositions and methods are provided for classification of individuals suffering from a demyelinating disease into groups that are informative of the individual's responsiveness or lack of responsiveness to treatment with a J3-interferon (IFNJ3) acting therapy. In particular, it is shown that the effective immunomodulatory treatment of demyelinating disease with IFNJ3 is associated with an increase in circulating transitional B cells in the patient. Diseases of interest include without limitation inflammatory demyelinating diseases of the central nervous system, e.g. multiple sclerosis, neuromyelitis optica (NMO), experimental autoimmune encephalitis (EAE), acute disseminated encephalomyelitis (ADEM), etc.

Author:

Robert Axtell

ISBN #:

0262050536

Author:

Robert Axtell

ISBN #:

0262550253

Author:

Robert L. Axtell

ISBN #:

0815724675

Author:

Robert L. Axtell

ISBN #:

0815724683